117 related articles for article (PubMed ID: 24518133)
1. Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma.
Dolman ME; den Hartog IJ; Molenaar JJ; Schellens JH; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2014 Apr; 92():144-8. PubMed ID: 24518133
[TBL] [Abstract][Full Text] [Related]
2. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma.
Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 925():124-8. PubMed ID: 23537694
[TBL] [Abstract][Full Text] [Related]
3. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.
Dolman ME; den Hartog IJ; Molenaar JJ; Schellens JH; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2014 Jan; 88():216-20. PubMed ID: 24080524
[TBL] [Abstract][Full Text] [Related]
4. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate.
Dolman ME; Westerhout EM; Hamdi M; Schellens JH; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2015 Mar; 107():403-8. PubMed ID: 25659532
[TBL] [Abstract][Full Text] [Related]
5. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
Sparidans RW; Tang SC; Nguyen LN; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():150-4. PubMed ID: 22940474
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.
Sparidans RW; van Hoppe S; Rood JJ; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Feb; 1012-1013():118-23. PubMed ID: 26826475
[TBL] [Abstract][Full Text] [Related]
7. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():174-7. PubMed ID: 22476054
[TBL] [Abstract][Full Text] [Related]
8. Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma.
Minematsu T; Felder L; Oppeneer T; Sakazume M; Oikawa K; Hashimoto T; Usui T; Kamimura H
Biomed Chromatogr; 2008 Jul; 22(7):763-9. PubMed ID: 18348340
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
Kawano H; Shakushiro K; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
Eur J Pharm Biopharm; 2014 Sep; 88(1):283-9. PubMed ID: 24993306
[TBL] [Abstract][Full Text] [Related]
10. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.
Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2014 Jan; 88():626-9. PubMed ID: 24216281
[TBL] [Abstract][Full Text] [Related]
11. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma.
Sparidans RW; Kort A; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1023-1024():24-9. PubMed ID: 27179188
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.
Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(32):4090-6. PubMed ID: 19910267
[TBL] [Abstract][Full Text] [Related]
13. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 889-890():144-7. PubMed ID: 22386128
[TBL] [Abstract][Full Text] [Related]
14. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.
Luethi D; Durmus S; Schinkel AH; Schellens JH; Beijnen JH; Sparidans RW
Biomed Chromatogr; 2014 Oct; 28(10):1366-70. PubMed ID: 24619951
[TBL] [Abstract][Full Text] [Related]
15. Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [
Mitsuoka K; Kita A; Murakami Y; Shirasuna K; Noda A; Yamanaka K; Kaneko N; Miyoshi S
Nucl Med Biol; 2018; 64-65():41-46. PubMed ID: 30041149
[TBL] [Abstract][Full Text] [Related]
16. Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates.
Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Oct; 878(28):2751-9. PubMed ID: 20829130
[TBL] [Abstract][Full Text] [Related]
17. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
Sparidans RW; Ahmed TT; Muilwijk EW; Welzen ME; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():137-40. PubMed ID: 22917595
[TBL] [Abstract][Full Text] [Related]
18. Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
Shakushiro K; Kawano H; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
Pharm Res; 2015 Jan; 32(1):238-47. PubMed ID: 25033765
[TBL] [Abstract][Full Text] [Related]
19. Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():169-73. PubMed ID: 22476055
[TBL] [Abstract][Full Text] [Related]
20. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
